Pfizer's stock has surged by 8.24% in the past month, but it has declined by 8.75% over the last year. The FDA's recent recommendation limits COVID-19 vaccines to seniors and those with certain medical conditions, which could negatively impact Pfizer's vaccine revenue. Despite strong financial performance in 2024 from COVID and non-COVID products, Pfizer's historical stock performance has disappointed shareholders with a 31% decline in five years. In 2025, total revenue is projected to be between $61 billion to $64 billion, with growth expected in oncology sales from late-stage drugs.
Pfizer's stock surged 8.24% over the past month, reducing its year-to-date loss to 5.02%, despite an 8.75% decline over the past year.
The FDA's recommendation of COVID-19 vaccines for only seniors and certain medical conditions may challenge Pfizer, which saw its COVID franchise contribute $11.1 billion in 2024.
Pfizer forecasts FY 2025 total revenues between $61 billion and $64 billion, with oncology sales expected to grow thanks to several late-stage development drugs.
Over the last five years, Pfizer shares have decreased by more than 31%, and since its peak on December 17, 2021, shares have fallen over 57%.
Collection
[
|
...
]